BRAF and neoplasm: Forty-four patients who underwent BRAF V600 testing showed a reduction in median OS from 32.1 months (95% CI 19.7–44.5 months) for BRAF wild-type tumours versus 17.2 months (95% CI 1.0–33.4) for BRAF mutant tumours (p = 0.109; Fig. 4).